Applied Filter(s) Clear Filter


Type:

Industry:

Therapy Area: Hematological Disorders

Category:

Global Polycythemia Vera Market

Report ID: PNPH1269 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The overall market size of Polycythemia Vera in the United States is expected to expand at a CAGR of 14% during the research period (2023-2030).PV is a condition that causes an increase in the amount of red blood cells in the bloodstream from a variety of factors. Itching, headache, dizziness, fatigue, blind spots, leukaemia, and, in rare cases, a heart attack induced by an atypical thrombotic event are all visible signs.

Global Diffuse Large B-cell Lymphoma Therapeutics Market

Report ID: PNPH1248 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Market refers to the market for drugs and therapies used in the treatment of diffuse large B-cell lymphoma, which is a type of aggressive non-Hodgkin lymphoma. The market size of DLBCL therapeutics was valued at USD 4,107.50 million in 2021.

Global Chronic Myeloid Leukemia (CML) Treatment Market

Report ID: PNPH1237 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The chronic myeloid leukemia (CML) treatment market is characterized by the presence of several effective therapies and ongoing research and development efforts. CML is a type of blood cancer caused by the abnormal growth of white blood cells. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have revolutionized the treatment landscape by effectively managing the disease and improving patient outcomes.

Global Chronic Myelogenous Leukaemia Treatment Market

Report ID: PNPH1236 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The global Chronic Myelogenous Leukaemia Treatment Market is expected to exhibit a CAGR of 6.0% during the forecast period (2023-2030) The Chronic Myelogenous Leukemia (CML) treatment market has witnessed significant advancements and growth over the years. CML is a type of blood cancer that affects the bone marrow and leads to the overproduction of abnormal white blood cells.

Global Chronic lymphocytic leukemia Market

Report ID: PNPH1235 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

Chronic lymphocytic leukemia Market is estimated to reach a CAGR of 6.01% over the forecast by 2023 – 2030.The chronic lymphocytic leukemia (CLL) market is a dynamic and evolving landscape characterized by continuous research and development activities. CLL is a type of blood cancer that affects the lymphocytes, a type of white blood cell.

Global Bruton Tyrosine Kinase (BTK) Inhibitors Market

Report ID: PNPH1233 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The market for Bruton tyrosine kinase (BTK) inhibitors is anticipated to experience significant growth in the coming years. BTK is a critical component of the B cell receptor (BCR) signaling pathway, and its dysregulation has been implicated in various B-cell lymphomas, including chronic lymphocytic leukemia (CLL).

Global Chronic Lymphocytic Leukemia Treatment Market

Report ID: PNPH1198 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The market size for treatments for chronic lymphocytic leukaemia was estimated at USD 4.9 billion in 2023. The market for treating chronic lymphocytic leukaemia is anticipated to increase from USD 5.3 billion in 2023 to USD 8.68 billion in 2030, with a compound annual growth rate (CAGR) of 8.52% over the five-year forecast period (2023–2030).

Global Bleeding Disorders Treatment Market

Report ID: PNPH1176 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

The bleeding disorders treatment was valued at USD 12.8 billion in 2021 and is projected to reach USD 18.6 billion by 2027, with a CAGR of 7.6% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies. 

Global Hemophilia Treatment Market

Report ID: PNPH1161 Industry: Pharma & Biotech Therapy Area: Hematological Disorders

Hemophilia is a commonly inherited group of bleeding disorders in which there is a problem with the blood clotting process. It can reflect sudden bleeding, continuous bleeding after surgery, and injuries. It contains various clotting factors that help stop bleeding, if there is any mutation in these clotting genes that mutation can inhibit the clotting protein factor, necessary to form a blood clot.

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!

Start-up
Profiling

One of our marquee services We profile relevant start-up companies in the market.

KOL
Insight's

Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.